Browsing Biomedical Research Center by Subject "AZD1222 (Oxford-AstraZeneca, ChAd)"
Now showing items 1-1 of 1
-
Comparable antibody levels in heterologous and homologous mRNA COVID-19 vaccination, with superior neutralizing and IgA antibody responses in mRNA homologous boosting
( Elsevier , 2024 , Article)BackgroundPriming with two doses of AZD1222 (Oxford-AstraZeneca; ChAd) followed by a third mRNA vaccine boosting is considered in several countries, yet comparisons between heterologous and homologous booster efficacy ...